In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Schwarz Pharma licensed exclusive US, Japanese, and European development and marketing rights to Ranbaxy Laboratories' RBx-2258 drug candidate for benign prostatic hyperplasia. The compound is in Phase I for the licensed territories, and in Phase II in India, where Ranbaxy retains rights.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?